WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
ACL injuries are more common in women soccer players than men. We may learn why
VOX POPULI: The power of old photos and a deficit
Princess of Wales: Data watchdog 'assessing' Kate privacy breach claims
Weather updates: Warnings across South Island, Taranaki, Coromandel, Bay of Plenty
Scammers stole more than $3.4 billion from older Americans last year, an FBI report says
VOX POPULI: The power of old photos and a deficit
Artificial intelligence found to be 'superior to biological intelligence'
Thousands of Russians join Navalny
Alicia Keys, Brian d’Arcy James, Daniel Radcliffe and more react to earning Tony Award nominations
Chinese hackers breached US ambassador to China's email account
Brit living in California shares how expensive it really is to live there
China is drilling some of the deepest holes in hunt for natural resources